Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB028050 in active rheumatoid arthritis patients with inadequate response to DMARDs: randomized double-blind placebo-controlled phase 2 trial
2009-011206-42Phase 2Completed
- Sponsor
- Incyte
- Start
- Jun 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (4 arms), sponsored by Incyte. Primary endpoint: Safety and tolerability. Started Jun 2009; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-011206-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011206-42.